← Back to all trials
Not Yet Recruiting
NCT07761286
Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
Conditions: HCC - Hepatocellular Carcinoma
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE1, PHASE2
Enrollment: 288
Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
Location: Harbin medical university Cancer Hospital Harbin Heilongjiang
Summary
This is an open-label, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of combination therapy with SYS6090 Injection in participants with hepatocellular carcinoma (HCC).
Eligibility Criteria
Inclusion Criteria:
1. The participant voluntarily signs the informed consent form.
2. Aged ≥18 years at the time of informed consent acquisition.
3. Confirmed diagnosis of hepatocellular carcinoma (HCC) via histopathology, cytopathology, or clinical diagnosis in accordance with the Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2026 Edition).
4. Barcelona Clinic Liver Cancer (BCLC) Stage C; or BCLC Stage B unsuitable for curative surgery and/or locoregional therapy.
5. Child-Pugh score \50 mL/min (calculated by the Cockcroft-Gault formula); urine protein \
Source: ClinicalTrials.gov (NCT07761286). StuddyBuddy aggregates publicly available trial information.
